VIVELLE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VIVELLE (VIVELLE).
Estradiol is an estrogen that binds to estrogen receptors, activating gene transcription and resulting in estrogenic effects in various tissues.
| Metabolism | Metabolized primarily via CYP3A4 to estrone and estriol; undergoes enterohepatic recirculation and conjugation (glucuronidation, sulfation). |
| Excretion | Estradiol is primarily metabolized in the liver to estrone and estriol, which are conjugated with glucuronic or sulfuric acid. Approximately 90% of the metabolites are excreted renally, with the remainder eliminated in the feces via biliary excretion. Less than 10% is excreted unchanged. |
| Half-life | The terminal elimination half-life of estradiol is approximately 12-24 hours, with a mean of about 14 hours. This supports once- or twice-weekly transdermal dosing, maintaining steady-state levels. |
| Protein binding | Estradiol is approximately 98% bound to plasma proteins, primarily to sex hormone-binding globulin (SHBG) and albumin. |
| Volume of Distribution | The apparent volume of distribution is approximately 1.2 L/kg, indicating extensive distribution into body tissues and fluids, including adipose tissue. |
| Bioavailability | Transdermal: Bioavailability is approximately 3-10% relative to oral administration due to avoidance of first-pass hepatic metabolism. Absolute bioavailability is about 80% compared to intravenous administration, as the drug is absorbed directly into systemic circulation. |
| Onset of Action | Transdermal: Clinical effects (e.g., relief of vasomotor symptoms) may be observed within 1-2 weeks of continuous therapy. Steady-state serum estradiol levels are achieved within 2-4 hours after patch application. |
| Duration of Action | Transdermal: Each patch provides sustained estradiol release for 3-4 days (84-96 hours). Replacement every 3.5 days (twice weekly) maintains continuous therapeutic levels. Clinical benefit persists as long as the patch is applied regularly. |
Transdermal, 0.0375 to 0.1 mg/day applied twice weekly (every 3-4 days); adjust dose based on response.
| Dosage form | FILM, EXTENDED RELEASE |
| Renal impairment | No specific dose adjustment required for renal impairment; use with caution in severe renal disease due to potential fluid retention. |
| Liver impairment | Contraindicated in severe hepatic disease (Child-Pugh class C). In moderate impairment (Child-Pugh B), start at lowest dose and monitor. |
| Pediatric use | Not indicated for use in pediatric patients; safety and efficacy not established. |
| Geriatric use | Use lowest effective dose; increase risk of thromboembolic events and dementia in women >65 years. Avoid use for prevention of chronic conditions. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for VIVELLE (VIVELLE).
| Breastfeeding | Estrogens are excreted in human breast milk in small amounts. The M/P ratio for estradiol is not well defined. Vivelle may reduce milk production and composition. Use during breastfeeding is not recommended, especially in the immediate postpartum period. Alternative methods of contraception should be considered. |
| Teratogenic Risk | Estrogen use during pregnancy is contraindicated. First trimester exposure has been associated with a potential increased risk of congenital anomalies, including cardiovascular defects and limb reduction defects. Second and third trimester use may increase risk of vaginal adenosis, cervical and vaginal clear cell adenocarcinoma in female offspring, and urogenital abnormalities in male offspring. Overall, estrogens should not be used during pregnancy. |
■ FDA Black Box Warning
Estrogen therapy increases the risk of endometrial cancer in women with an intact uterus. Unopposed estrogen use is associated with increased risk of endometrial hyperplasia and carcinoma. Estrogen plus progestin therapy has been associated with increased risk of breast cancer, stroke, and deep vein thrombosis/pulmonary embolism.
| Serious Effects |
["Undiagnosed abnormal genital bleeding","Known, suspected, or history of breast cancer","Known or suspected estrogen-dependent neoplasia","Active DVT, PE, or history of these conditions","Active arterial thromboembolic disease (e.g., stroke, MI) or history","Known protein C, protein S, or antithrombin deficiency or other thrombophilic disorders","Hepatic impairment or disease","Known or suspected pregnancy"]
| Precautions | ["Cardiovascular disorders (stroke, DVT, PE): increased risk","Malignant neoplasms: endometrial cancer, breast cancer","Dementia: possible increased risk in women >65 years","Gallbladder disease","Hypercalcemia in patients with breast cancer and bone metastases","Retinal vascular thrombosis","Fluid retention","Exacerbation of endometriosis","Exacerbation of asthma, diabetes, epilepsy, migraine, porphyria, SLE, hepatic hemangiomas","Hypothyroidism: estrogen increases thyroid-binding globulin, may require thyroid hormone dose adjustment"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, weight, and signs of thrombosis. Assess for adverse effects such as nausea, headache, and edema. No specific fetal monitoring is required if pregnancy occurs, but pregnancy testing should be performed if pregnancy is suspected. Inadvertent exposure during pregnancy necessitates counseling and ultrasound for fetal anatomy. |
| Fertility Effects | Estrogen replacement therapy does not impair fertility. In women with ovarian failure, exogenous estradiol can support endometrial growth for embryo implantation when used with progestogens. However, use for contraception is not indicated. |